Blog

Sep 14, 2024, 06:56

Bishoy Morris Faltas: The Faltas Lab at Weill Cornell Medicine is seeking motivated postdoctoral fellows and research associates to join our dynamic team

Bishoy Morris Faltas, Weill Cornell Medicine, shared on X:

“The Faltas Lab at Weill Cornell Medicine in New York City is seeking motivated postdoctoral fellows and research associates to join our dynamic team. The Faltas lab focuses on the mechanisms that induce genome instability in urothelial cancer, the resulting intra-tumor heterogeneity, and the evolution of drug resistance and metastasis. We use a multidisciplinary approach by integrating experimental models, such as cell lines, patient-derived organoids, and animal models, with cutting-edge computational biology techniques. Research from the Faltas Lab has been published in Nature and other high-impact journals. The lab is supported by grants from the NCI (R37 MERIT award funding for the next 7 years), the Department of Defense, the Starr Cancer Consortium, and the Bladder Cancer Advocacy Network.

Based in New York City, our team thrives in a vibrant, culturally rich environment, offering numerous networking and academic opportunities in this global hub of innovation. We offer competitive salaries (higher than the postdoctoral NIH stipend). Weill Cornell Medicine provides comprehensive benefits, including health, dental, and vision insurance coverage and subsidized housing. Mentoring is a priority for Dr. Faltas, and the laboratory offers a rich and diverse scientific environment for professional development.

Ongoing and future projects in the lab include:
1.    Investigating the mechanisms by which APOBEC3 cytidine deaminase mutagenic enzymes drive intra-tumor heterogeneity and the biological function of APOBEC3-induced mutations and RNA-editing.
2.    Investigating the role of structural variants, such as extrachromosomal DNA, in the evolution of therapy resistance.
3.    Bio-Digital Avatars for Personalized Sequencing of Bladder Cancer Therapies.
4.    Translational projects leveraging our findings for personalized therapy and drug development for patients with urothelial and other cancers.
Ideal candidates:
·     Ph.D. in molecular biology, cell biology, biochemistry, pharmacology, or related fields with a strong background in cancer biology.
·     Excellent skills in basic molecular biology and biochemical techniques, including cloning, SDS-PAGE western blotting, qPCR, functional assays, and mammalian cell culture.
·     Experience in mouse handling and experiments, such as tumor xenograft models and tail vein injections, is a plus.
·     Familiarity with basic R or Python is a plus but not required.
·     Excellent communication, organizational, and problem-solving skills.
·     Track record of productivity (publications) from Ph.D. is a plus.
Interested applicants are encouraged to send their CV, a statement of research interests, copies of previous publications, and names and contact information of three references to Dr. Bishoy M. Faltas.”

Yan Leyfman shared this post adding:

“A passionate mentor who is invested in trainee success while still propelling the field of GU oncology to new heights. Consider this unique opportunity.”

Source: Yan Leyfman/LinkedIn and Bishoy Morris Faltas/LinkedIn

Yan Leyfman MD, is the Co founder and executive director of MedNews Week. He is also the Medical correspondent at OncLive. He is also the Executive Committee Member at Music Beats Cancer. He is a Clinical Researcher at Icahn School of Medicine at Mount Sinai. His research interests include oncology, Immunooncology, Cellular Therapy, and Immunotherapy.

Bishoy Morris Faltas Bladder Cancer Advocacy Network cancer GU Oncology New York City OncoDaily Oncology The Faltas Lab the Starr Cancer Consortium Weill Cornell Medicine

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage